Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab plus chemotherapy in refractory Ewing's sarcoma
2022-003812-98Phase 2Active
- Sponsor
- Institute of Mother and Child
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of naxitamab in Ewing sarcoma (2 arms), sponsored by Institute of Mother and Child. Primary endpoint: Safety and tolerability of naxitamab plus chemotherapy. Started Jan 2023; status: active.
02
Drugs
naxitamab
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on 2022-003812-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003812-98.